Orthocell Limited
Orthocell Limited
Your view on OCC.AX
Overview
What the company does, where it operates, and who runs it.
About Orthocell Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Frederick Anderson
- Headquarters
- Building 191, Murdoch, WA, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Paul Frederick Anderson
- Headquarters
- Building 191, Murdoch, WA, AU
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries.
The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries.
Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle.
Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Orthocell Limited. Starting points for Orthocell Limited: EPS -AUD 0.05, beta -0.07 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Orthocell Limited. Orthocell Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Orthocell Limited. Trailing twelve-month EPS for Orthocell Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Earnings Estimate
| EPS | Current QtrSep 2023 | Next QtrDec 2023 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 0.00 | AUD 0.00 | −AUD 0.05 | −AUD 0.02 |
| Low estimate | AUD 0.00 | AUD 0.00 | −AUD 0.05 | −AUD 0.03 |
| High estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | −AUD 0.02 |
| No. of analysts | 0 | 0 | 1 | 1 |
| Year-ago EPS | — | — | −AUD 0.05 | — |
| Growth | — | — | +10.3% | — |
Revenue Estimate
| Revenue | Current QtrSep 2023 | Next QtrDec 2023 | Current YearFY Jun 2027 | Next YearFY Jun 2028 |
|---|---|---|---|---|
| Avg. estimate | AUD 4.25M | AUD 4.25M | AUD 15.95M | AUD 30.65M |
| Low estimate | AUD 4.25M | AUD 4.25M | AUD 15.00M | AUD 24.10M |
| High estimate | AUD 4.25M | AUD 4.25M | AUD 16.90M | AUD 37.20M |
| No. of analysts | 1 | 1 | 2 | 2 |
| Year-ago revenue | — | — | AUD 11.41M | — |
| Growth | — | — | +39.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Orthocell Limited. Orthocell Limited has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ARX.AXAroa Biosurgery Limited | Healthcare | Medical - Devices | — | ||
| CMB.AXCambium Bio Limited | Healthcare | Biotechnology | — | ||
| OSX.AXOsteopore Limited | Healthcare | Medical - Instruments & Supplies | — | ||
| PNV.AXPolyNovo Limited | Healthcare | Medical - Devices | — | ||
| TRP.AXTissue Repair Ltd | Healthcare | Biotechnology | — | ||
| TTX.AXTetratherix Ltd. | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $373.3M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.8M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $9.3B | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Orthocell Limited. Coverage tracks Orthocell Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Orthocell Limited.